Search Results - "Baert, Thais"

Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer by du Bois, Andreas, Baert, Thaïs, Vergote, Ignace

Get full text

Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients by Baert, Thaïs, Van Camp, Joke, Vanbrabant, Lisa, Busschaert, Pieter, Laenen, Annouschka, Han, Sileny, Van Nieuwenhuysen, Els, Vergote, Ignace, Coosemans, An

“…The effect of CA125, neutrophil to lymphocyte ratio (NLR) and thrombocytosis on survival has been studied in ovarian cancer. This study explores the link…”
Get full text

TRP channel expression correlates with the epithelial–mesenchymal transition and high-risk endometrial carcinoma by Van den Eynde, Charlotte, De Clercq, Katrien, Van Bree, Rieta, Luyten, Katrien, Annibali, Daniela, Amant, Frédéric, Han, Sileny, Van Nieuwenhuysen, Els, Baert, Thaïs, Peeraer, Karen, Voets, Thomas, Van Gorp, Toon, Vriens, Joris

“…Transient receptor potential (TRP) channels excel in cellular sensing as they allow rapid ion influx across the plasma membrane in response to a variety of…”
Get full text

Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas by Glorie, Nathalie, Baert, Thaïs, VAN DEN Bosch, Thierry, Coosemans, A N

“…Uterine sarcomas are rare but very aggressive. Uterine myomas, on the other hand, are the most common benign tumors of the uterus. Currently there is no…”
Get full text

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial by Loverix, Liselore, Vergote, Ignace, Busschaert, Pieter, Vanderstichele, Adriaan, Venken, Tom, Boeckx, Bram, Harter, Philipp, Brems, Hilde, Van Nieuwenhuysen, Els, Pignata, Sandro, Baert, Thaïs, Gonzalez-Martin, Antonio, Han, Sileny, Marth, Christian, Neven, Patrick, Colombo, Nicoletta, Berteloot, Patrick, Mäenpää, Johanna, Olbrecht, Siel, Laga, Tina, Sablon, Erwin, Ray-Coquard, Isabelle, Pujade-Lauraine, Eric, Lambrechts, Diether, Van Gorp, Toon

“…The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive patients…”
Get full text

Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation – real life data by Ataseven, Beyhan, Tripon, Denise, Schwameis, Richard, Harter, Philipp, Rhiem, Kerstin, Schneider, Stephanie, Heikaus, Sebastian, Baert, Thaïs, Francesco, Alesina Pier, Heitz, Florian, Traut, Alexander, Groeben, Harald-Thomas, Schmutzler, Rita, du Bois, Andreas

“…We evaluated the clinical impact of germline (g)BRCA1/2-mutation on initial disease presentation, surgical implications, surgical morbidity and survival in…”
Get full text

Improving Endometrial cancer assessment by combining the new techniqUe of GENomic profiling with surgical Extra uterIne disEase assessment (EUGENIE) by Kasius, Jenneke C, Trozzi, Rita, Pijnenborg, Johanna, Baert, Thaïs, Laenen, Annouschka, Van Rompuy, Anne-Sophie, Zapardiel, Ignacio, Vizzielli, Giuseppe, Knez, Jure, Fanfani, Francesco, Amant, Frédéric

“…The molecular classification of endometrial cancer revolutionized our knowledge of its biology but so far has not affected our surgical approach. The exact…”
Get more information

Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role? by De Bruyn, Christine, Baert, Thaïs, Van den Bosch, Thierry, Coosemans, An

“…Purpose of Review Uterine cancer comprises endometrial carcinoma and the uterine sarcoma. Endometrial carcinomas are the most frequent variant and have early…”
Get full text

Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery by Landolfo, Chiara, Ceusters, Jolien, Valentin, Lil, Froyman, Wouter, Van Gorp, Toon, Heremans, Ruben, Baert, Thaïs, Wouters, Roxanne, Vankerckhoven, Ann, Van Rompuy, Anne-Sophie, Billen, Jaak, Moro, Francesca, Mascilini, Floriana, Neumann, Adam, Van Holsbeke, Caroline, Chiappa, Valentina, Bourne, Tom, Fischerova, Daniela, Testa, Antonia, Coosemans, An, Timmerman, Dirk, Van Calster, Ben

“…Background Several diagnostic prediction models to help clinicians discriminate between benign and malignant adnexal masses are available. This study is a…”
Get full text

Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients by Ramspott, Jan Philipp, Baert, Thaïs, MacKintosh, Michelle Louise, Traut, Alexander, Ataseven, Beyhan, Bommert, Mareike, Heitz, Florian, Plett, Helmut, Schneider, Stephanie, Waltering, Kai-Uwe, Heikaus, Sebastian, Harter, Philipp, du Bois, Andreas

“…Purpose The chemotherapy response score (CRS) is a histopathological tool to evaluate response to neoadjuvant chemotherapy (NACT) in high-grade serous ovarian…”
Get full text

Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study by Plett, Helmut, Filippova, Olga T., Garbi, Annalisa, Kommoss, Stefan, Rosendahl, Mikkel, Langstraat, Carrie, Phadnis, Saurabh, Muallem, Mustafa Zelal, Baert, Thaïs, Chi, Dennis S., Aletti, Giovanni Damiano, Taran, Florin-Andrei, Ramspott, Jan Philipp, Zivanovic, Oliver, du Bois, Andreas, Sonoda, Yukio, Gardner, Ginger, Traut, Alexander, Long Roche, Kara, Harter, Philipp

“…Standard of care in patients with advanced ovarian cancer (AOC) is upfront surgery followed by chemotherapy. Neoadjuvant chemotherapy (NACT) and interval…”
Get full text

Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience by Pauly, Nina, Baert, Thaïs, Schmutzler, Rita, du Bois, Andreas, Schneider, Stephanie, Rhiem, Kerstin, Schömig-Markiefka, Birgid, Siemanowski, Janna, Heikaus, Sebastian, Traut, Alexander, Heitz, Florian, Prader, Sonia, Ehmann, Sarah, Harter, Philipp, Ataseven, Beyhan

“…Purpose Current guidelines for Lynch syndrome detection in endometrial cancer (EC) patients rely either on risk evaluation, based on personal/family history,…”
Get full text

A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial by Ottenbourgs, Tine, van Gorp, Toon, Kridelka, Frédéric, Baert, Thaïs, Denys, Hannelore, Selle, Frédéric, Baas, Inge, Van Rompuy, Anne-Sophie, Lambrechts, Diether, Van Nieuwenhuysen, Els

“…Low-grade serous and endometrioid ovarian cancers and adult-type granulosa cell tumors are rare ovarian malignancies that show high estrogen receptor…”
Get more information

Low-grade Serous Tumors: Are We Making Progress? by Pauly, Nina, Ehmann, Sarah, Ricciardi, Enzo, Ataseven, Beyhan, Bommert, Mareike, Heitz, Florian, Prader, Sonia, Schneider, Stephanie, du Bois, Andreas, Harter, Philipp, Baert, Thaïs

“…Purpose of Review This review provides an overview of the current clinical standard in low-grade serous ovarian cancer (LGSOC). The available evidence for…”
Get full text

Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer by Van Baelen, Karen, Nguyen, Ha-Linh, Hamy-Petit, Anne-Sophie, Richard, François, Karsten, Maria Margarete, Marta, Guilherme Nader, Vermeulen, Peter, Toussaint, Aullene, Reyal, Fabien, Vincent-Salomon, Anne, Dirix, Luc, Dordevic, Adam David, de Azambuja, Evandro, Larsimont, Denis, Amato, Ottavia, Maetens, Marion, De Schepper, Maxim, Geukens, Tatjana, Han, Sileny N., Baert, Thaïs, Punie, Kevin, Wildiers, Hans, Smeets, Ann, Nevelsteen, Ines, Floris, Giuseppe, Biganzoli, Elia, Neven, Patrick, Desmedt, Christine

“…Invasive lobular carcinoma (ILC) represents up to 15% of all breast carcinomas. While the proportion of women with overweight and obesity increases globally,…”
Get full text

Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer by De Bruyn, Christine, Ceusters, Jolien, Landolfo, Chiara, Baert, Thaïs, Thirion, Gitte, Claes, Sandra, Vankerckhoven, Ann, Wouters, Roxanne, Schols, Dominique, Timmerman, Dirk, Vergote, Ignace, Coosemans, An

“…In monotherapy, immunotherapy has a poor success rate in ovarian cancer. Upgrading to a successful combinatorial immunotherapy treatment implies knowledge of…”
Get full text

Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course by Coosemans, An, Decoene, Judit, Baert, Thaïs, Laenen, Annouschka, Kasran, Ahmad, Verschuere, Tina, Seys, Sven, Vergote, Ignace

“…Neoplastic cells can escape immune control leading to cancer growth. Regulatory T cells (Treg), myeloid-derived suppressor cells (MDSC) and tumor-associated…”
Get full text

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience by Moubarak, Malak, Harter, Philipp, Ataseven, Beyhan, Traut, Alexander, Welz, Julia, Baert, Thais, Heitz, Florian

“…•Real-life data support prospective evidence that 2nd PARPi therapy can be beneficial.•Patients who do not meet OREO criteria might also benefit from a PARPi…”
Get full text

Low-grade Serous Ovarian Carcinoma by Ricciardi, Enzo, Baert, Thaïs, Ataseven, Beyhan, Heitz, Florian, Prader, Sonia, Bommert, Mareike, Schneider, Stephanie, du Bois, Andreas, Harter, Philipp

“…In the early 2000s a two-tier grading system was introduced for serous ovarian cancer. Since then, we have increasingly come to accept that low-grade serous…”
Get full text

Ovarian cancer and the immune system by Baert, T, Vergote, I, Coosemans, A

“…Abstract Short communication in response to the review of Turner et al. entitled "Ovarian cancer and the immune system - the role of targeted therapies"…”
Get full text